Having trouble accessing articles? Reset your cache.

Green Valley’s Alzheimer’s drug targeting gut-brain-axis gets Chinese approval

In the latest step away from targeting amyloid, China’s National Medical Products Administration (NMPA) granted conditional approval for a gut microbiome-targeting drug from Green Valley to treat mild-to-moderate Alzheimer’s disease.

Shanghai Green Valley Pharmaceutical Co. Ltd.

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers